/
Immunology
Graft Versus Host Disease
55
Pipeline Programs↗
89
Active Trials↗
46
Companies Involved↗
Graft Versus Host Disease is a moderately active landscape with 55 programs across 46 companies. The most active players are Astellas, MaaT Pharma. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 15
Phase 228
Phase 312
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
38 of 47 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 98% of 55 pipeline programs.
Analysis
Trial Status
343
clinical trials
Completed149 · 43%
Terminated48 · 14%
Recruiting41 · 12%
Unknown status39 · 11%
Active, not recruiting27 · 8%
Not yet recruiting18 · 5%
Other21 · 6%
Clinical Trials
Trial Activity
343 trials
A Phase I Trial of Ex Vivo-Expanded (EVE) Regulatory T Cells in Combination With Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Recruiting·—·Phase 1·NCT06991361·21 enrolled
Page 1 of 23
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)